OnKure Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

OKUR$2.87+13.5%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	March 31,	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$96,661	$110,761
Prepaid expenses and other current assets	1,511	2,242
Total current assets	98,172	113,003
Property and equipment, net	925	1,025
Operating lease right-of-use asset	676	770
Other assets	109	109
Total assets	$99,882	$114,907
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$2,344	$2,968
Accrued expenses	5,895	7,026
Operating lease liabilities, current portion	546	536
Total current liabilities	8,785	10,530
Long-term operating lease liabilities	409	549
Other long-term liabilities	40	—
Total liabilities	9,234	11,079
Commitments and contingencies
Stockholders’ equity:
Common stock, Class A, $0.0001 par value; 200,000,000 shares authorized; 12,755,348 and 12,660,590 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	1	1
Common stock, Class B, $0.0001 par value; 10,000,000 shares authorized; 686,527 shares issued and outstanding at both March 31, 2025 and December 31, 2024	—	—
Additional paid-in capital	261,296	258,551
Accumulated deficit	(170,649)	(154,724)
Total stockholders’ equity	90,648	103,828
Total liabilities and stockholders’ equity	$99,882	$114,907

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.